A nationwide comprehensive genomic profiling and molecular tumor board platform for patients with advanced cancer.

The Belgian Approach for Local Laboratory Extensive Tumor Testing (BALLETT) study assessed the feasibility of using comprehensive genomic profiling (CGP) in clinical decision-making for patients with advanced cancers. This multi-center study enrolled 872 patients from 12 Belgian hospitals. CGP was performed on tumor tissues using a standardized CGP panel (523 genes) across nine laboratories with success in 93% of patients and a median turnaround time of 29 days.

Can transcranial direct current stimulation (tDCS) over the motor cortex increase endurance running performance? a randomized crossover-controlled trial.

Transcranial direct current stimulation (tDCS), a non-invasive brain stimulation technique, has been shown to increase exercise performance in strength and cycling studies but its effects on running endurance remain unclear. The objectives of this randomized sham-controlled crossover trial were to assess tDCS efficacy on submaximal treadmill running time to exhaustion (TTE). Forty-five healthy male runners aged between 18 and 32 years (mean maximal oxygen consumption: 46.

Surveillance of Disease Progression in Metastatic Breast Cancer by Molecular Counting of Circulating Tumor DNA Using Plasma-SeqSensei Breast Cancer in Vitro Diagnostics Assay.

Circulating tumor DNA (ctDNA) quantification surpasses cancer antigen 15 to 3 for metastatic breast cancer surveillance. Clinical translation, however, is limited because of uncertainties about the optimal method and clinically valid ctDNA decision thresholds. Plasma-SeqSensei Breast Cancer IVD kit (PSS) is a novel assay for ctDNA molecular counting, detecting ≥0.